Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received an average rating of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $24.00.

Several brokerages have recently weighed in on CLBT. Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Needham & Company LLC lifted their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Lake Street Capital boosted their target price on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Bank of America raised their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th.

Hedge Funds Weigh In On Cellebrite DI

Hedge funds have recently modified their holdings of the business. Venturi Wealth Management LLC increased its stake in Cellebrite DI by 5.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 14,700 shares of the company’s stock worth $272,000 after buying an additional 700 shares during the period. CWM LLC grew its stake in shares of Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after acquiring an additional 720 shares in the last quarter. Blue Trust Inc. increased its position in shares of Cellebrite DI by 4.0% during the third quarter. Blue Trust Inc. now owns 23,121 shares of the company’s stock worth $428,000 after acquiring an additional 898 shares during the period. SkyView Investment Advisors LLC raised its stake in shares of Cellebrite DI by 2.6% in the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after acquiring an additional 970 shares in the last quarter. Finally, Fox Run Management L.L.C. boosted its holdings in Cellebrite DI by 3.9% in the second quarter. Fox Run Management L.L.C. now owns 30,359 shares of the company’s stock valued at $486,000 after purchasing an additional 1,127 shares during the period. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $14.94 on Wednesday. Cellebrite DI has a one year low of $13.10 and a one year high of $25.47. The stock has a market cap of $3.58 billion, a PE ratio of 48.19, a P/E/G ratio of 2.04 and a beta of 1.28. The stock has a 50 day moving average price of $17.29 and a 200 day moving average price of $17.02.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The company had revenue of $126.03 million for the quarter, compared to analyst estimates of $122.98 million. During the same period last year, the firm posted $0.14 EPS. The business’s quarterly revenue was up 17.9% on a year-over-year basis. As a group, analysts predict that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.